CClinicalTrials.gg
CompletedNCT00042926Updated Dec 7, 2016

Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer

An interventional study of immunohistochemistry staining method and conventional surgery in Head and Neck Cancer, sponsored by Alliance for Clinical Trials in Oncology. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-07.

Sponsored by Alliance for Clinical Trials in Oncology · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
161
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

RATIONALE: Diagnostic procedures to detect cancer cells in sentinel lymph nodes may help plan effective cancer treatment.

PURPOSE: Diagnostic trial to study the effectiveness of lymph node mapping and sentinel lymph node lymphadenectomy in patients who are undergoing surgery to remove early-stage cancer of the mouth.

Read the detailed description

OBJECTIVES:

  • Determine whether a negative hematoxylin and eosin finding from the lymphatic mapping and sentinel node lymphadenectomy procedure accurately predicts the negativity of the other cervical lymph nodes in patients with stage I or II squamous cell carcinoma of the oral cavity.
  • Determine the extent and pattern of disease spread in the nodal bed in these patients.
  • Obtain data on the use of immunohistochemistry to assess nodes in these patients.
02

Conditions studied

  • Head and Neck Cancer

Keywords

  • stage I squamous cell carcinoma of the lip and oral cavity
  • stage II squamous cell carcinoma of the lip and oral cavity
03

In context

Head and Neck Neoplasms

2,344 studies on the registry are indexed under Head and Neck Neoplasms; 551 are open to participants now.

This study's enrollment of 161 is above the median of 47 across 1,751 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

Alliance for Clinical Trials in Oncology is the lead sponsor of 499 studies on the registry; 27 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patient must be > 18 years of age.
  2. Patient must have an ECOG/Zubrod performance status of \< 2.
  3. Patient must have a histologically confirmed primary T1 or T2 invasive OCSCCA that is > 6mm and \< 4 cm in size. The primary tumor must be amenable to curative resection and must be diagnosed within 42 days prior to surgery.
  4. Patient must be clinically stage N0 confirmed with a negative imaging study employing contrastenhanced CT scan (or MRI with gadolinium in patients with iodine allergy). Lymph nodes will be considered positive if:

    • Greater than 1.5 cm in size for levels I and II.
    • Greater than 1 cm in size for levels III, IV, V and VI.
    • If any lymph node exhibits central necrosis, irregular enhancement of a poorly defined or irregular capsular border.
    • Groups of three or more asymmetrically located LNs, with a minimal axial diameter of 8 mm or more, in the suspected tumor drainage area are present.
    • NOTE: All CT scans must be read by a neuroradiologist.
  5. Patient must be medically fit for neck dissection.
  6. Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration or any study-related procedures.
  7. Female patient of childbearing potential must have negative serum pregnancy test within 30 daysprior to registration.
  8. If the patient is a survivor of a prior cancer, ALL of the following criteria are met:

    1. Patient has undergone potentially curative therapy for all prior malignancies,
    2. No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone),
    3. Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.

Exclusion criteria

Exclusion Criteria:

  1. Patient received prior treatment to the cervical lymph nodes, including surgery or radiation therapy.
  2. Patient experienced prior extensive trauma to the anterior cervical region of the neck.
  3. Patient has lesions that cross the vermilion border involving lip skin.
  4. Patient has had previous tumor resection involving the neck.
  5. Patient has had injections of radioactive material for previous scans within 48 hours of the radiolymphoscintigraphy.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Radiolymphoscintigraphy + surgery

    Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H\&E) staining. If negative by H\&E, lymph nodes are further analyzed by immunohistochemistry. Patients are followed at 30 days.

    Other: immunohistochemistry staining method · Procedure: conventional surgery · Procedure: lymphangiography · Procedure: radionuclide imaging · Procedure: sentinel lymph node biopsy · Radiation: technetium Tc 99m sulfur colloid

Interventions

  • Otherimmunohistochemistry staining method
  • Procedureconventional surgery
  • Procedurelymphangiography
  • Procedureradionuclide imaging
  • Proceduresentinel lymph node biopsy
  • Radiationtechnetium Tc 99m sulfur colloid
06

What researchers measure

Primary outcomes

  1. Proportion of non-SLN(s) negative patients

    Time frame: Up to 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol. 2010 Mar 10;28(8):1395-400. doi: 10.1200/JCO.2008.20.8777. Epub 2010 Feb 8. PubMed 20142602 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00042926
Lead sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
May 2002
Primary completion
May 2007
Completion
Nov 2010
Last update
Dec 7, 2016

Study contacts

Francisco Civantos, MD
study chair · University of Miami Sylvester Comprehensive Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion